Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics, Inc.

SAN FRANCISCO AND BOSTON, MARCH 26, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,750,000 SHARES OF ITS COMMON STOCK, INCLUDING THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE UP TO 750,000 ADDITIONAL SHARES, AT A PUBLIC OFFERING PRICE PER SHARE OF $70.00. THE AGGREGATE GROSS PROCEEDS TO APOGEE FROM THE OFFERING WERE APPROXIMATELY $403 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY APOGEE.

APOGEE THERAPEUTICS, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES FOR GROSS PROCEEDS OF $403 MILLION

SAN FRANCISCO AND BOSTON, MARCH 24, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,000,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE PER SHARE OF $70.00. THE AGGREGATE GROSS PROCEEDS TO APOGEE FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $350 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY APOGEE. THE OFFERING IS EXPECTED TO CLOSE ON MARCH 26, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. IN ADDITION, APOGEE HAS GRANTED THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 750,000 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

APOGEE THERAPEUTICS, INC. ANNOUNCES PRICING OF $350 MILLION UNDERWRITTEN PUBLIC OFFERING

SAN FRANCISCO AND BOSTON, MARCH 23, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $300 MILLION OF SHARES OF ITS COMMON STOCK. IN ADDITION, APOGEE EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $45 MILLION OF SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE PROPOSED PUBLIC OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING. ALL OF THE SHARES OF COMMON STOCK ARE BEING OFFERED BY APOGEE.

APOGEE THERAPEUTICS, INC. ANNOUNCES PROPOSED $300 MILLION UNDERWRITTEN PUBLIC OFFERING

APEX PART A DATA DEMONSTRATED DURABLE MAINTENANCE OF RESPONSE AT 52-WEEKS FOR EVERY 3- AND 6-MONTHS DOSING, RESPECTIVELY, INCLUDING: - 75% AND 85% PATIENTS MAINTAINED EASI-75 - 86% AND 78% PATIENTS MAINTAINED VIGA 0/1 DEEPENING OF RESPONSE WAS OBSERVED ACROSS ALL LESIONAL AND ITCH ENDPOINTS WITH BOTH EVERY 3- AND 6- MONTH DOSING AMONG THE FULL POPULATION OF PATIENTS INITIALLY RANDOMIZED TO ZUMILOKIBART

APOGEE THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 PART A 52-WEEK DATA OF ZUMILOKIBART (APG777), DEMONSTRATING MAINTENANCE AND DEEPENING OF RESPONSES WITH EVERY 3- AND 6-MONTH DOSING IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

SAN FRANCISCO AND BOSTON, MARCH 22, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED IT WILL REPORT PART A 52-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF ZUMILOKIBART ON MONDAY, MARCH 23, 2026. FOLLOWING THE ANNOUNCEMENT, THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:00 A.M.

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT PART A 52-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF ZUMILOKIBART (APG777) IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS ON MARCH 23, 2026

ZUMILOKIBART (APG777) TRIALS CONTINUE TO ADVANCE IN ATOPIC DERMATITIS (AD) WITH PLANS FOR EXPANSION INDICATIONS UNDERWAY: - APEX PHASE 2 PART A 52-WEEK DATA EXPECTED THIS MONTH - APEX PHASE 2 PART B 16-WEEK DATA EXPECTED IN Q2 2026 - PHASE 3 TRIAL INITIATION IN AD ANTICIPATED IN 2H 2026 - SUCCESSFUL EXPANSION OF ZUMILOKIBART BEYOND AD DEMONSTRATED IN ASTHMA PHASE 1B TRIAL; DETAILS ON ASTHMA AND EOSINOPHILIC ESOPHAGITIS ( EOE) TRIALS EXPECTED LATER THIS YEAR PHASE 1B HEAD-TO-HEAD TRIAL OF APG279 (ZUMILOKIBART + APG990) VS. DUPIXENT UNDERWAY, WITH INTERIM AD DATA ANTICIPATED IN 2H 2026 STRONG TOTAL CASH POSITION OF $902.9 MILLION WITH RUNWAY INTO 2H 2028 SUPPORTS ADVANCEMENT TOWARD POTENTIAL LAUNCH OF ZUMILOKIBART IN 2029 SAN FRANCISCO AND BOSTON, MARCH 02, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY PROVIDED PIPELINE PROGRESS AND REPORTED FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS.

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS FULL YEAR 2025 FINANCIAL RESULTS

SAN FRANCISCO AND BOSTON, FEB. 24, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE ON TUESDAY, MARCH 3, 2026, AT 9:10 A.M. E.T. MANAGEMENT WILL ALSO ATTEND THE UBS BIOTECH SUMMIT MIAMI, CATALYST FOR CHANGE ON MONDAY, MARCH 9, 2026, AND THE JEFFERIES BIOTECH ON THE BEACH SUMMIT ON TUESDAY, MARCH 10, 2026.

APOGEE THERAPEUTICS TO PARTICIPATE IN UPCOMING MARCH CONFERENCES

SAN FRANCISCO AND BOSTON, FEB. 05, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT 2026 ON THURSDAY, FEBRUARY 12, 2026, AT 2:00 P.M. E.T. A LIVE AND ARCHIVED WEBCAST OF THE FIRESIDE CHAT WILL BE AVAILABLE VIA THE NEWS & EVENTS PAGE IN THE INVESTORS SECTION OF THE APOGEE THERAPEUTICS WEBSITE.

APOGEE THERAPEUTICS TO PARTICIPATE AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT 2026

PHASE 1B INTERIM RESULTS OF ZUMILOKIBART (APG777) IN ASTHMA DEMONSTRATED RAPID AND DURABLE SUPPRESSION OF FENO (KEY BIOMARKER OF TYPE 2 INFLAMMATION) THROUGH 16 WEEKS FOR ALL PATIENTS - SUPPRESSION OF FENO THROUGH 32 WEEKS FOR PATIENTS WITH AVAILABLE FOLLOW UP - RESULTS REINFORCE CONTINUED DEVELOPMENT IN ASTHMA TESTING EVERY 3- OR 6-MONTH DOSING

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 1B TRIAL OF ZUMILOKIBART (APG777), ITS POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA AND HIGHLIGHTS 2026 ANTICIPATED MILESTONES AND OUTLOOK

SAN FRANCISCO AND BOSTON, JAN. 05, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED IT WILL REPORT INTERIM RESULTS FROM ITS PHASE 1B TRIAL OF APG777 IN PATIENTS WITH MILD-TO-MODERATE ASTHMA ON TUESDAY, JANUARY 6, 2026. FOLLOWING THE ANNOUNCEMENT, THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:00 A.M.

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG777 IN PATIENTS WITH MILD-TO-MODERATE ASTHMA AND 2026 ANTICIPATED MILESTONES ON JANUARY 6, 2026

Apogee Therapeutics, Inc.

APGE

Price

Financial Reports

No items found.

Press Releases

Apogee Therapeutics, Inc.

APGE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

APGE